Glioblastoma is the most common form of primary brain cancer in adults, with a median survival rate of 12-15 months. Although nearly all glioblastomas recur, initial treatments may keep the tumor controlled for months or even years. MGMT promoter methylation has been shown to be associated with improved outcomes in glioblastoma patients, especially after treatment with alkylating chemotherapy.
This is due to the role of MGMT as a DNA repair enzyme. Inactivation of MGMT expression by methylation results in a decrease in DNA repair capabilities, leading to greater sensitivity to alkylating agents. To quantify CpG methylation within the MGMT gene promoter, researchers used bisulfite modification of tumor DNA and real-time PCR. Therefore, our MGMT methylation tests can help guide clinicians with treatment decisions.